Products Press Releases Partnering Careers Contact

Featured Post

Kye Pharmaceuticals Secures Exclusive Canadian License, Supply and Commercialization Agreement for a novel proton pump inhibitor (PPI) treatment option for gastroesophageal reflux disease (GERD) in infants, children and adults

May 1, 2025

May 1, 2025

Kye Pharmaceuticals Secures Exclusive Canadian License, Supply and Commercialization Agreement for a novel proton pump inhibitor (PPI) treatment option for gastroesophageal reflux disease (GERD) in infants, children and adults

April 8, 2025

New Drug Submission for AGAMREE® (vamorolone) Accepted for Priority Review by Health Canada for the Treatment of Duchenne Muscular Dystrophy

March 11, 2025

ACCRUFeR® (ferric maltol) is now available in Canada as a prescription oral treatment for iron deficiency anemia.

August 29, 2024

Kye Pharmaceuticals Announces the Availability of QUILLIVANT® ER Oral Suspension for the Treatment of Children With ADHD

August 27, 2024

Kye Pharmaceuticals announces approval in Canada for ACCRUFeR® (ferric maltol) for the treatment of iron deficiency anemia in adult patients

July 24, 2024

Kye Pharmaceuticals Secures Exclusive License, Supply and Commercialization Agreement with Catalyst Pharmaceuticals for AGAMREE®, a novel treatment for Duchenne muscular dystrophy, in Canada